Trillium Therapeutics Inc (TRIL) is near the top in its industry group according to InvestorsObserver. TRIL gets an overall rating of 66. That means it scores higher than 66 percent of stocks. Trillium Therapeutics Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 45 out of 148 industries.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Trillium Therapeutics Inc Stock Today?
Trillium Therapeutics Inc (TRIL) stock is lower by -2.89% while the S&P 500 has risen 0.53% as of 10:02 AM on Tuesday, Feb 11. TRIL is down -$0.10 from the previous closing price of $3.57 on volume of 168,469 shares. Over the past year the S&P 500 has risen 24.35% while TRIL has risen 179.84%. TRIL earned $2.58 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 1.34.
